EDGC is showing strong performance. The news that the company is achieving results while developing customized new drugs based on AI-based genome analysis methods appears to be influencing its stock price.
As of 11:45 AM on the 1st, EDGC is trading at 1,700 KRW, up 7.05% from the previous day.
EDGC plans to disclose for the first time the results of its evaluation of the efficacy of anticancer drug candidates on lymphoma, after receiving approval to present at the upcoming ‘European Society for Medical Oncology (ESMO) 2023’ conference in October.
The EDGC New Drug Development Institute will reveal the efficacy of anticancer drug candidates ‘EC-352H’ and ‘EC-374H’ against lymphoma. ‘EC-352H’ and ‘EC-374H’ are anticancer candidates discovered based on epigenetic biomarkers owned by EDGC. These substances have also shown excellent efficacy in prostate cancer, and based on related efficacy evaluation results, domestic and U.S. patents were registered in 2018.
The EDGC New Drug Development Institute stated that these anticancer candidates minimize toxicity to normal cells while specifically inhibiting the proliferation of lymphoma cells, thereby preventing lymphoma tumor growth.
In preclinical and non-clinical experiments, when these drug candidates were administered to laboratory mice, only normal levels of weight gain were observed during the drug treatment period, and visible toxic reactions were significantly low. EDGC explained that this is noteworthy as it overcomes the chronic problem of toxicity to normal cells seen in existing competing anticancer drugs, while maintaining high efficacy.
At the EDGC New Drug Development Institute, using the AI-based genome analysis method of the epigenetic biomarker platform Epicatch, methylation changes in cancer patients are analyzed to discover biomarkers and develop customized targeted new drugs through patient clinical trials. To diversify the candidate pipeline and enhance indications, research is ongoing not only on lymphoma but also on colorectal cancer and refractory solid tumors.
Kim Yeon-jeong, head of the EDGC New Drug Development Institute, said, "We are honored to demonstrate the excellent efficacy of the anticancer drug candidates held by the EDGC New Drug Development Institute at the European Society for Medical Oncology, where cancer researchers from around the world gather." She emphasized, "We will elevate corporate value through new drug development combined with liquid biopsy-based genome analysis and lead the domestic bio industry."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
